Who are Atea Pharmaceuticals, Inc.'s main suppliers?

Atea Pharmaceuticals, Inc. (AVIR) key suppliers include: MERCK-CO-INC, MSD-INTERNATIONAL-GMBH. View the full supplier network at chainsifter.com/chain/AVIR.

Who are Atea Pharmaceuticals, Inc.'s major customers?

Atea Pharmaceuticals, Inc. (AVIR) key customers include: Gilead Sciences, Inc., Gilead Sciences, Inc., Merck & Co., Inc., Merck & Co., Inc., F-HOFFMANN-LA-ROCHE-LTD and 3 more. View the full customer network at chainsifter.com/chain/AVIR.

What sector is Atea Pharmaceuticals, Inc. in?

Atea Pharmaceuticals, Inc. (AVIR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Atea Pharmaceuticals, Inc. (AVIR) Suppliers & Customers

2Suppliers

8Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Atea Pharmaceuticals, Inc. (AVIR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

13Total relationships

1Distinct source URLs

5High confidence

0.762Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Atea Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
MERCK-CO-INC	MERCK-CO-INC	92%	In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.
MSD-INTERNATIONAL-GMBH	MSD-INTERNATIONAL-GMBH	92%	In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.

Atea Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
GILD	Gilead Sciences, Inc.	72%	ed to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our developmen…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from GILD g…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from MRK graph: Reciprocal relationship from AVIR graph: Reciprocal relationship from MRK grap…
MRK	Merck & Co., Inc.	72%	rary in in vitro and in vivo studies to assess the antiviral activity and other properties of such compounds against other RNA viral infections. In all our discovery and preclinical efforts, we asses…
F-HOFFMANN-LA-ROCHE-LTD	F-HOFFMANN-LA-ROCHE-LTD	62%	ors, CROs, consultants, vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and comme…
GILEAD-PHARMASSET-LLC	GILEAD-PHARMASSET-LLC	62%	ors, CROs, consultants, vendors and any third parties we may engage in connection with research, development, regulatory, manufacturing, quality assurance and other pharmaceutical functions and comme…
GILEAD-SCIENCES-INC-ASEGUA-THERAPEUTICS-LLC	GILEAD-SCIENCES-INC-ASEGUA-THERAPEUTICS-LLC	62%	ed to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our developmen…
MSD-INTERNATIONAL-GMBH	MSD-INTERNATIONAL-GMBH	62%	rary in in vitro and in vivo studies to assess the antiviral activity and other properties of such compounds against other RNA viral infections. In all our discovery and preclinical efforts, we asses…

Atea Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
AVIR-DEBT-7994	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.
AVIR-DEBT	Debt stack $634,000	90%	Market cache reports total debt of $634,000.

Atea Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
AVIR-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 129 tracked holders.

Atea Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ZTS	Zoetis Inc.	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	2
CAH	Cardinal Health, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
CRIS	Curis, Inc.	100.00	2
ENLV	Enlivex Ltd.	100.00	2
IMMP	Immutep Limited	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
PSNL	Personalis, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
EVAX	Evaxion A/S	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
VEEV	Veeva Systems Inc.	100.00	2
ADAG	Adagene Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
TBPH	Theravance Biopharma, Inc.	100.00	2

Atea Pharmaceuticals, Inc. Supply Chain